Why the study?
Does oral apixaban improve the treatment of cancer-associated venous thromboembolism without increasing major bleeding compared to subcutaneous dalteparin?
Does oral apixaban improve the treatment of cancer-associated venous thromboembolism without increasing major bleeding compared to subcutaneous dalteparin?
Oral apixaban provides a noninferior, oral alternative to subcutaneous dalteparin for the treatment of cancer-associated VTE without increasing major bleeding risk.
Supports oral apixaban for cancer-associated VTE; challenges prior low-certainty evidence against its benefit.
Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding. (Funded by the Bristol-Myers Squibb-Pfizer Alliance; Caravaggio ClinicalTrials.gov number, NCT03045406.).
No takes yet. Share an insight, caveat, or question.
Agnelli et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: